Can-Fite BioPharma, Ltd.
4:15 PM - 4:30 PM (EST), Tuesday, February 7, 2023 ・ Palace
Can-Fite is an advanced clinical stage drug development Company with a platform oral drug technology designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. Its lead drug candidate, Piclidenoson, was found safe and effective in a Phase III trial for psoriasis, and a pivotal Phase III psoriasis trial for market approval is now under preparation. Can-Fite's liver drug, Namodenoson, is in a pivotal Phase III trial for liver cancer and a Phase IIb trial for the treatment NASH. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
Ticker:
CANF
Exchange:
NYSE American
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
Not Provided
Main Therapeutic Focus:
Dermatology
Lead Product in Development:
Piclidenoson and Namodenoson
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
